Small Molecules
10 September 2024
New results from the Investigational agent BAY 2927088 in HER2-mutant non-small cell lung cancer (NSCLC) presented at WCLC9 September 2024
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival6 September 2024
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease5 September 2024
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)3 September 2024
Evommune Initiates Phase 2 Trial of EVO756, an Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria3 September 2024
Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections29 August 2024
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia28 August 2024
Yunovia Announces IND Approval by the MFDS to Initiate Phase 1 MAD Study for the Small Molecule GLP-1 Agonist26 August 2024
SIFI Receives European Commission Approval for AKANTIOR®23 August 2024
European Commission approves BALVERSA® (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma22 August 2024
iOmx Therapeutics Initiates Phase Ib with OMX-040722 August 2024
Bayer initiates Phase II study of soluble guanylate cyclase activator (BAY3283142) in patients with chronic kidney diseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports